Seven Italian Biotechs to Know About in 2026
Italy’s biotech sector, though less visible, hosts several companies poised for global impact in 2026. AAVantgarde Bio secured a $141 million Series B to launch dual‑AAV gene therapies for Stargardt disease and Usher syndrome, while Genenta Science rebranded as Saentra Forge to broaden into defense and aerospace. Milan‑based Genespire raised €46.6 million to advance its immune‑shielded lentiviral platform for methylmalonic acidemia, and IAMA Therapeutics entered Phase 1 with an NKCC1 inhibitor for autism and epilepsy. Established player Philogen continues late‑stage immunocytokine trials despite withdrawing its EMA application for Nidlegy.
Evaluating Vyvgart®’s Impact on Myasthenia Gravis in Spain
A recent multi‑criteria decision analysis by Cortés‑Vicente et al. evaluates Vyvgart® (efgartigimod alfa) for generalized myasthenia gravis (gMG) in Spain. The study finds the Fc‑fragment therapy lowers pathogenic antibodies, improves muscle strength, and boosts health‑related quality‑of‑life. Safety compares favorably to...
Hospital Stay and Outcomes in CNS Lymphoma Study
French researchers conducted a retrospective multicenter analysis of primary central nervous system lymphoma patients, linking hospital length of stay to survival outcomes. The study found that longer admissions often reflected more intensive chemotherapy regimens, which were associated with improved survival,...
Uncovering Ochratoxin A’s Role in Liver Cancer
Recent research has identified a stronger causal link between chronic exposure to the mycotoxin Ochratoxin A (OTA) and the development of hepatocellular carcinoma. The study combined long‑term rodent feeding trials with analysis of human liver biopsies, revealing a dose‑dependent increase...
Link Between Oral Health and Dementia in Seniors
A new ten‑year longitudinal study of 5,000 seniors found that individuals with poor oral hygiene were 30% more likely to develop dementia. Researchers detected periodontal bacteria DNA in brain tissue of participants who later exhibited cognitive decline. The analysis controlled...
Recognizing Pediatric Chordoma’s Poorly Differentiated Subtype
Researchers have identified a distinct poorly differentiated subtype of pediatric chordoma, characterized by loss of SMARCB1 (INI1) expression and unique histologic features. Advanced imaging reveals heterogeneous, infiltrative patterns that differ from classic chordoma presentations. Early clinical data suggest that conventional...
Multicondition Profiling Challenges Role of Housekeeping Genes
A new multicondition profiling study demonstrates that traditional housekeeping genes are not uniformly stable across diverse biological states. By analyzing thousands of RNA‑seq datasets, researchers found significant expression fluctuations in genes long used for normalization. The findings call into question...
Science-Led CX: Why Proof Builds Loyalty in Health Retail
Health‑focused retailers are moving beyond flashy trends to a science‑led customer experience, where proof of efficacy replaces hype. Consumers in wellness, skincare and family‑health categories now demand clinical backing, clear ingredient origins and regulatory compliance before they commit. Brands like...
Exploring Metastatic Salivary Gland Carcinoma Insights
Researchers at a tertiary care center have completed comprehensive molecular profiling of metastatic and recurrent salivary gland carcinoma, identifying key gene mutations, copy-number changes, and fusions that correlate with tumor aggressiveness and patient survival. The study also maps the tumor...
Zalcitabine Triggers Ferroptosis in Multiple Myeloma Cells
Researchers have discovered that the antiviral drug zalcitabine can trigger ferroptosis, an iron‑dependent form of cell death, in multiple myeloma cells. Laboratory experiments showed significant lipid‑peroxide accumulation and loss of viability at micromolar concentrations. The effect was amplified when zalcitabine...
Broadening T Cell Control in Atopic Dermatitis
Corvus Pharmaceuticals reported Phase I efficacy for its oral ITK inhibitor soquelitinib in 24 atopic dermatitis patients who had failed prior therapies. The drug targets upstream T‑cell activation, diverging from the cytokine‑blocking strategy of market leaders Dupixent and Rinvoq. Investors...
L-Fucose: A Sugar with Cancer Therapy Potential
Researchers are investigating L‑fucose, a rare monosaccharide, as a novel adjunct in cancer therapy. Pre‑clinical models show that supplementing L‑fucose can modulate tumor glycosylation, enhancing immune recognition and reducing metastatic spread. Early phase trials report improved response rates when L‑fucose...
Hormonal Contraceptives Influence Women’s Jealousy and Competition
New research published in Journal of Evolutionary Psychology shows that hormonal contraceptives significantly alter women's emotional responses, increasing jealousy toward perceived rivals and amplifying competitive drives. The study, which surveyed over 1,200 women across multiple countries, found that synthetic estrogen...
2026 Catalysts: Psychiatry, Epilepsy and Neurodegeneration
The 2026 catalyst calendar for neuroscience highlights a surge of late‑stage readouts in psychedelics, epilepsy, and genetically driven neurodegeneration. The analysis, based on a 25‑slide deck, points to upcoming Phase III trials, regulatory decisions, and proof‑of‑concept data that could unlock new...
Scientists Develop Technique to Identify Malfunctions in Our Genetic Code
An international research team, led by scientists from ANU, unveiled a silicon‑nanopore technique that watches transfer‑RNA (tRNA) molecules in real time. By squeezing over three million tRNA samples through tiny membrane holes, the method captures how single‑letter mutations reshape the...
Mapping Mitochondrial Regulators to Combat Α-Synucleinopathy
A recent study published by bioengineer.org identifies a network of mitochondrial regulators that modulate α‑synuclein aggregation, a hallmark of Parkinson’s disease and related neurodegenerative disorders. Using CRISPR‑based screens and proteomic profiling, researchers pinpointed five key proteins that restore mitochondrial dynamics...
CMS Picks Lilly’s Trulicity, Gilead's Biktarvy for Third Round of Medicare Negotiations
CMS announced the selection of Eli Lilly’s GLP‑1 diabetes drug Trulicity and Gilead’s HIV therapy Biktarvy for the third round of Medicare drug price negotiations under the Inflation Reduction Act. The program, now in its third cycle, expands the list...
Vitamin D Links to Neonatal Hypocalcemia: A Six-Year Study
A six‑year, multi‑center cohort study has identified a strong link between maternal vitamin D deficiency and neonatal hypocalcemia. Infants born to mothers with serum vitamin D below 20 ng/mL were significantly more likely to present low calcium levels within the first...
Impact of Alcohol Use on HIV Prevention Adherence
Recent studies reveal that alcohol consumption significantly undermines adherence to HIV prevention regimens, particularly pre‑exposure prophylaxis (PrEP). Heavy drinkers miss up to 30% more doses and are less likely to attend follow‑up appointments. The relationship persists across diverse demographics, driven...
Novel Nanomaterial Uses Oxidative Stress to Kill Cancer Cells
Scientists at Oregon State University have engineered an iron‑based metal‑organic framework that simultaneously generates hydroxyl radicals and singlet oxygen within cancer cells, exploiting the acidic, hydrogen‑peroxide‑rich tumor microenvironment. This dual‑reactive‑oxygen‑species approach achieved complete tumor regression in mice bearing human breast...
Scalable Mobility-Based Contact Matrices for Pandemic Modeling
A research team has unveiled a scalable framework that builds contact matrices directly from real‑time mobility data, enabling more granular pandemic modeling. The approach dynamically adjusts interaction patterns as people move, and can be applied to national‑scale populations without prohibitive...
Synthetic 'Muscle' With Microfluidic Blood Vessels Shows Promise for Soft Robotics
Researchers at the University of Nebraska–Lincoln have unveiled a hydrogel‑based actuator that mimics biological muscle by embedding microgel units within a microfluidic circulatory network. The system delivers rapid chemical or thermal stimuli, allowing actuation in non‑aqueous environments and achieving faster...
Gut Bacteria in Animal Models of Parkinson’s Disease
Recent pre‑clinical studies reveal that gut microbiota profoundly influence Parkinson’s disease (PD) pathology in animal models. Germ‑free mice exhibit reduced α‑synuclein aggregation, while colonisation with PD‑patient fecal material accelerates motor deficits and neuroinflammation. Specific bacterial taxa and their metabolites, particularly...
Net-Casting Spiders' Adjustable Silk Stiffness Point to Tunable Fiber Design
Researchers from Greifswald, Bonn and Buenos Aires have shown that net‑casting spiders actively adjust silk stiffness by altering the microstructure of individual threads. By adding crinkled, “curly” fibers to elastic strands, the spiders create a silk that stretches up to...
Hospitals Could Earn More for Buying US-Made Drugs, CMS Proposes
The Centers for Medicare & Medicaid Services (CMS) has unveiled a proposal to raise hospital reimbursement rates for drugs that are manufactured in the United States. Under the plan, the outpatient prospective payment system would grant higher payments for domestically...
Unified Platform Enhances Variant Detection in Mendelian Genetics
Researchers led by Du et al. unveiled an integrated platform that concurrently detects structural variants and single‑nucleotide polymorphisms. The system leverages machine‑learning algorithms to boost copy‑number variation detection and uncover pathogenic alleles in Mendelian families lacking diagnoses. By handling large‑scale...
Cardiff Execs Depart as Company Drops Mixed Phase 2 Data
Cardiff Oncology (CRDF) saw its shares tumble more than 30% after it released mixed Phase 2 results for its lead oncology candidate. The trial met several secondary endpoints but failed to achieve its primary efficacy goal, prompting uncertainty about the...
Reconfigurable Robotic Fish Reveals How Stiffness and Wave Propagation Shape Swimming Performance
A team at Peking University built a soft robotic fish that can reconfigure between eel‑like (anguilliform) and tuna‑like (carangiform) swimming styles. By adjusting body stiffness, the platform directly measured how wave propagation and stiffness affect thrust, speed, and maneuverability. In...
Assessing New Training for Mental Health Care Staff
A new study by Crous, Kanareck, Thomas and colleagues evaluates an educational program that equips mental‑health staff to lead advance‑care‑planning conversations with older adults suffering from mental illness. The curriculum combines workshops, role‑playing, and digital tools to improve knowledge of...
US Withdrawal From WHO Creates New Pharma Logistics Vulnerabilities
The United States formally withdrew from the World Health Organization on January 22, 2026, citing alleged failures and politicization. The exit threatens to fracture the global regulatory framework that pharmaceutical companies rely on for drug approval and quality standards. It also jeopardizes...
New Technology Solves Production Bottleneck for Black Soldier Fly Larvae
Texas A&M researchers unveiled the patented Black Soldier Fly Billet, a pint‑sized, room‑temperature storage system that keeps newborn larvae viable for weeks or months. The sealed container combines fermented feed, larvae, and a dry food blanket, extending the typical two‑to‑four‑day...
Navigating the Operational Tightrope in Pharmaceutical Manufacturing
Raj Puri, chief commercial officer of Argonaut Manufacturing, warns that tariffs, soaring U.S. investment and compressed product timelines are forcing CDMOs onto a tight operational rope. A seven‑figure tariff on key equipment illustrates how trade policy can cripple ROI calculations...
FDA Lifts Hold on One of Two Phase 3 Gene Editing Studies by Intellia
Intellia Therapeutics received FDA clearance to resume one of its two pivotal Phase 3 gene‑editing trials targeting hereditary transthyretin amyloidosis (hATTR). The agency had placed a partial clinical hold earlier this year over safety concerns, but after additional data the hold...
FDA Lifts One of Two Clinical Holds on Intellia’s ATTR Gene Editing Program
The U.S. Food and Drug Administration lifted its clinical hold on Intellia Therapeutics' MAGNITUDE‑2 Phase III trial of the CRISPR‑based therapy nex‑z for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv‑PN). The company announced that patient enrollment will resume, prompting a 10 % rise...
GSK’s RSV Vaccine Approved in Europe
GSK’s adjuvanted recombinant RSV vaccine Arexvy received European Commission approval on Jan. 26, 2026 for all adults 18 years and older, expanding beyond its prior indication for seniors and high‑risk 50‑59‑year‑olds. The EU estimates roughly 158,000 adult RSV‑related hospitalisations each year, underscoring the...
AstraZeneca Ends Work on Cardio Drug; Lisata and Qilu Terminate Deal
AstraZeneca has terminated its Phase II cardiovascular drug program, pulling the study from the clinical pipeline. The decision coincides with the simultaneous dissolution of a collaboration between biotech Lisata and Chinese partner Qilu, ending a joint development effort. Both moves...
China Clears Its First Drug for Chronic Hepatitis D
Huahui Health’s libevitug has secured conditional approval from China’s NMPA, marking the nation’s first domestically approved drug for chronic hepatitis D. The antibody blocks the PreS1 domain of HBV and HDV, preventing viral entry into liver cells. Previously, only Gilead’s Hepcludex...
How the University of North Carolina at Chapel Hill Is Enhancing RNAi Potency with Its New Technology
The University of North Carolina at Chapel Hill has unveiled a DNA‑based platform that adds deoxythymidine (dT) overhangs to the 5′ end of the antisense strand of siRNAs. This modification dramatically improves guide‑strand loading into the RNA‑induced silencing complex, delivering...
Baseline Debuts To Challenge GLP-1 Giant Lilly in Alcohol Use Disorder
Baseline Therapeutics, a San Francisco biotech, has launched its GLP‑1 analog BT‑001 to treat alcohol use disorder (AUD). The company has secured FDA alignment and will begin two randomized, placebo‑controlled Phase III trials this year. Baseline also plans to expand BT‑001 into...
Interpreting Caregiving Photos with Multimodal AI Models
A new multimodal AI system can analyze caregiving photographs, extracting contextual cues such as patient posture, environment safety, and medication usage. The model, trained on millions of annotated images, achieves roughly 92% accuracy in identifying risk factors like falls or...
How Automated NLP Pipelines Cut Oncology Data Abstraction From Weeks to Hours
Cognizant’s senior data scientist Abhijit Nayak explains why transformer models that shine on curated oncology NLP benchmarks falter in clinical settings. He highlights that real‑world pathology reports and clinical notes are highly heterogeneous, demanding modular extraction pipelines with robust validation,...
FDA Greenlights Life Biosciences' Gene Therapy Study to Rewind the Age of Cells
The U.S. Food and Drug Administration has granted Life Biosciences IND clearance to begin a first‑in‑human gene‑therapy trial aimed at reversing cellular aging. The study will test an epigenetic reprogramming platform that delivers modified mRNA encoding Yamanaka factors to rejuvenate...
Boehringer Signs €1bn+ Deal for Simcere IBD Candidate
Boehringer Ingelheim has licensed SIM0709, a bispecific antibody targeting IL‑23p19 and TL1A, from China’s Simcere in a deal valued at up to €1.05 billion. The agreement includes a €42 million upfront payment and milestone‑based payouts. SIM0709 is in pre‑clinical development and aims...
Vaspin’s Role in Gestational Diabetes and Insulin Resistance
A recent study by Zhang et al. demonstrates that the adipokine Vaspin can attenuate insulin resistance in gestational diabetes by modulating oxidative stress and nitric‑oxide pathways. In vitro and in vivo experiments showed Vaspin lowers reactive oxygen species and enhances endothelial...
Multi-Omics Uncover Soil Microbe Blooms in Snowmelt
A multinational research team applied metagenomics, metatranscriptomics and metabolomics to alpine soils and discovered a dramatic, short‑lived bloom of microbes during spring snowmelt. The analysis pinpointed fast‑growing bacterial families such as Pseudomonadaceae and Burkholderiaceae that surged by up to 150‑fold...
Roche’s Obesity Shot Posts Decent Weight Loss in Mid-Stage Test, Heads to Phase 3
Roche’s most advanced obesity candidate achieved an average 18.3% weight reduction in a Phase 2 study after nearly a year of treatment. The trial enrolled patients with moderate to severe obesity and demonstrated sustained efficacy without major safety signals. Based on...
Why Owning the Learning Loop Matters More Than Owning the Lab
Nimbus Therapeutics, founded in 2009, has built a successful small‑molecule drug engine without owning any laboratories, relying on a Design‑Make‑Test‑Analyze (DMTA) learning loop executed through CRO partners. By keeping hypothesis generation, molecular design, data integration and decision‑making in‑house, the company...
Roche Claims Midstage Win for Obesity Injectable
Roche announced phase‑2 results for its dual GIP/GLP‑1 obesity drug CT‑388, showing a placebo‑adjusted 22.5% weight loss at the 24 mg dose after 48 weeks. More than half of participants fell below the obesity BMI threshold, and 96% lost at least...
Assessing Hearing Loss in Chronic Myeloid Leukemia Treatments
A recent multi‑center study evaluated the incidence of hearing loss among patients receiving chronic myeloid leukemia (CML) tyrosine‑kinase inhibitors (TKIs). The analysis of 1,200 patients over five years found a 7% clinically significant ototoxicity rate, most pronounced with second‑generation TKIs....
RSV’s Soluble G Protein Drives Viral Spread via TLR2
Researchers have identified that the soluble G protein of respiratory syncytial virus (RSV) directly engages Toll‑like receptor 2 (TLR2), facilitating viral dissemination. The interaction triggers TLR2‑dependent signaling that dampens interferon‑mediated antiviral defenses, boosting RSV replication in cultured airway cells. Inhibition...
